Shares of DBV Technologies launched Wednesday after the company reported promising results for its peanut allergy treatment.

DBV Technologies (ENXTPA:DBV) has scheduled a special call to unpack the VITESSE trial results and outline next steps for its Viaskin Peanut program, putting fresh attention on the company’s late ...

DBV Technologies stock rallied on Wednesday following analyst price target increases after the company’s latest clinical trial news.

DBV received a complete response letter from the FDA in August 2020, citing adhesion and efficacy concerns with the patch.

Châtillon, France, December 16, 2025DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in ...

Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy to market in the US as the first alternative to Stallergenes Greer's ...

DBV Technologies SA said its experimental skin patch helped young children with a peanut allergy in a crucial study.

DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers ...

DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study ...

Avec Les Echos suivez en temps réel toute l'actualité financière puisée aux meilleures sources des sociétés cotées sur les bourses de Paris, Bruxelles, Amsterdam, Lisbonne, Francfort et New York.